Dynavax Technologies Co. (NASDAQ:DVAX) Shares Sold by Texas Permanent School Fund Corp

Texas Permanent School Fund Corp cut its stake in Dynavax Technologies Co. (NASDAQ:DVAX) by 14.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 96,748 shares of the biopharmaceutical company’s stock after selling 16,380 shares during the period. Texas Permanent School Fund Corp owned approximately 0.07% of Dynavax Technologies worth $1,086,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Kynam Capital Management LP grew its holdings in Dynavax Technologies by 180.0% in the 1st quarter. Kynam Capital Management LP now owns 4,239,780 shares of the biopharmaceutical company’s stock valued at $52,616,000 after buying an additional 2,725,397 shares in the last quarter. Eventide Asset Management LLC grew its holdings in shares of Dynavax Technologies by 103.0% in the fourth quarter. Eventide Asset Management LLC now owns 2,893,435 shares of the biopharmaceutical company’s stock valued at $40,450,000 after purchasing an additional 1,468,435 shares during the period. Goldman Sachs Group Inc. increased its position in Dynavax Technologies by 21.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 3,597,139 shares of the biopharmaceutical company’s stock worth $50,288,000 after purchasing an additional 644,428 shares during the last quarter. UBS Group AG raised its stake in Dynavax Technologies by 427.2% during the fourth quarter. UBS Group AG now owns 647,911 shares of the biopharmaceutical company’s stock worth $9,058,000 after purchasing an additional 525,012 shares during the period. Finally, Mizuho Markets Americas LLC boosted its holdings in Dynavax Technologies by 37.9% in the 2nd quarter. Mizuho Markets Americas LLC now owns 1,175,107 shares of the biopharmaceutical company’s stock valued at $13,196,000 after purchasing an additional 323,050 shares during the last quarter. Institutional investors and hedge funds own 96.96% of the company’s stock.

Wall Street Analyst Weigh In

DVAX has been the subject of a number of recent analyst reports. The Goldman Sachs Group cut their price target on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a report on Thursday, August 8th. StockNews.com downgraded Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, May 28th. Finally, HC Wainwright reiterated a “buy” rating and set a $29.00 price target on shares of Dynavax Technologies in a report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.67.

Dynavax Technologies Stock Performance

NASDAQ:DVAX opened at $11.35 on Friday. Dynavax Technologies Co. has a fifty-two week low of $9.74 and a fifty-two week high of $15.15. The company has a debt-to-equity ratio of 0.35, a quick ratio of 13.18 and a current ratio of 14.18. The company has a 50 day moving average price of $11.05 and a 200 day moving average price of $11.48. The stock has a market capitalization of $1.49 billion, a P/E ratio of 189.17 and a beta of 1.37.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.06 by $0.02. The business had revenue of $73.80 million during the quarter, compared to analyst estimates of $76.92 million. Dynavax Technologies had a return on equity of 2.76% and a net margin of 6.88%. During the same period last year, the business posted $0.03 earnings per share. Equities research analysts forecast that Dynavax Technologies Co. will post 0.16 EPS for the current year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.